Blue Earth Therapeutics develops next‑generation radiopharmaceutical therapies for metastatic castration‑resistant prostate cancer by combining a PSMA ligand with radio‑hybrid molecules labeled with either beta‑emitting lutetium‑177 or alpha‑emitting actinium‑225. Their engineered compounds improve tumor affinity and pharmacokinetics, enabling higher therapeutic radiation doses to cancer cells while minimizing exposure to healthy organs. The company advances these agents through preclinical work and early‑phase clinical trials to demonstrate safety, dosimetry, and anti‑tumor activity.
Funding
$76.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
3OSCFounders
Product
Problem
Current radiopharmaceutical therapies for cancer, especially prostate cancer, are limited by the inability to deliver sufficiently high radiation doses to tumors without causing unacceptable damage to healthy organs. This constraint reduces treatment efficacy and hampers patient outcomes.
Solution
Blue Earth Therapeutics develops next‑generation targeted radiopharmaceuticals that combine a prostate‑specific membrane antigen (PSMA) ligand with radio‑hybrid molecules labeled with either beta‑emitting lutetium‑177 or alpha‑emitting actinium‑225. By engineering the linker, chelator, and albumin‑binding properties, the compounds achieve higher tumor affinity, improved internalization, and favorable biodistribution, allowing higher therapeutic radiation doses to be deposited in cancer cells while sparing normal tissue. The company advances these agents through preclinical studies and early‑phase clinical trials (Phase 1 and Phase 2) to demonstrate safety, dosimetry, and anti‑tumor activity in metastatic castration‑resistant prostate cancer.
Target Audience
Healthcare professionals and oncology centers developing or delivering radioligand therapy for prostate cancer, as well as research institutions investigating targeted alpha and beta radiopharmaceuticals.
Features
- Radio‑hybrid PSMA‑targeted molecules (rhPSMA‑10.1) incorporating a PSMA ligand, chelator, and optimized linker for enhanced tumor binding and clearance.
- Dual isotopic platform: beta emitter ^177Lu for conventional radioligand therapy and alpha emitter ^225Ac for high‑LET, short‑range cell killing.
- Engineered albumin‑binding and charge modulation to improve pharmacokinetics and reduce off‑target organ exposure.
- Preclinical and clinical validation pipeline, including dosimetry studies and Phase 1/2 trials in metastatic castrate‑resistant prostate cancer (NCT05413850).
- Manufacturing partnership with Seibersdorf Labor GmbH to ensure GMP‑grade production and global supply chain reliability.